Histomorphometric and microarchitectural analyses using the 2 mm bone marrow trephine in metastatic breast cancer patients-preliminary results

Journal of Bone Oncology

Volumn 1, Issue 3, 2012, Pages 69-73

  Fralick, M ^a   Bouganim, N ^b   Kremer, R ^b   Kekre, N ^c   Robertson, S ^c   Vandermeer, L ^c   Kuchuk, I ^c   Li, J ^d   Murshed, M ^d   Clemons, M ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c OTTAWA REGIONAL CANCER CENTRE   (Canada)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

Bisphosphonate; Breast cancer; Histomorphometry; Microarchitecture; MicroCT

Indexed keywords

AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE;

ADULT; ARTICLE; BONE DENSITY; BONE MARROW BIOPSY; BONE METASTASIS; BONE STRUCTURE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER INVASION; CANCER PATIENT; CASE REPORT; CLINICAL TRIAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MICRO-COMPUTED TOMOGRAPHY; MORPHOMETRICS; NEEDLE; NEEDLE BIOPSY; OSTEOCLAST ACTIVITY; PILOT STUDY; PRIORITY JOURNAL; STRUCTURE ANALYSIS; TRABECULAR BONE;

EID: 84875615705     PISSN: 22121374     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbo.2012.10.003     Document Type: Article

References (33)

1. Coleman RE, McCloskey EV. Bisphosphonates in oncology. Bone 2011;49(1): 71-6.
2. Lewiecki EM. Safety of long-term bisphosphonate therapy for the management of osteoporosis. Drugs 2011;71(6):791-814.
3. Schilcher J, Michaelsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. New England Journal of Medicine 2011;364(18): 1728-37.
4. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. Journal of the American Medical Association 2001;285(6):785-795.
5. Rivadeneira F, Zillikens MC, De Laet CE, Hoiman A, Uitterlinden AG, Beck TJ, et al. Femoral neck BMD is a strong predictor of hip fracture susceptibility in elderly men and women because it detects cortical bone instability: the Rotterdam Study. Journal of Bone and Mineral Research 2007;22(11):1781-90.
6. Yang L, Peel N, Clowes JA, McCloskey EV, Eastell R. Use of DXA-based structural engineering models of the proximal femur to discriminate hip fracture. Journal of Bone and Mineral Research 2009;24(1):33-42.
7. Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. American Journal of Medicine 2002;112(4):281-9.
8. Sandhu SK, Hampson G. The pathogenesis, diagnosis, investigation and management of osteoporosis. Journal of Clinical Pathology 2011;64(12):1042-50.
9. Chavassieux P, Seeman E, Delmas PD. Insights into material and structural basis of bone fragility from diseases associated with fractures: how determinants of the biomechanical properties of bone are compromised by disease. Endocrine Reviews 2007;28(2):151-64.
10. Currey JD. Changes in the impact energy absorption of bone with age. Journal of Biomechanics 1979;12(6):459-69.
11. Vashishth D. Age-dependent biomechanical modifications in bone. Critical Reviews in Eukaryotic Gene Expression 2005;15(4):343-58.
12. Bilezkian JP, Raisz LG, Martin TJ. Principles of bone biology. Oxford, United Kingdom: Elsevier; 2008.
13. Hilton JF, Amir E, Hopkins S, Nabavi M, DiPrimio G, Sheikh A, et al. Acquisition of metastatic tissue from patients with bone metastases from breast cancer. Breast Cancer Research and Treatment 2011;129(3):761-5.
14. Moore RJ, Durbridge TC, Woods AE, Vernon-Roberts B. Comparison of two bone trephine instruments used for quantitative histomorphometry. Journal of Clinical Pathology 1989;42(2):213-5.
15. Khavandgar Z, Poirier C, Clarke CJ, Li J, Wang N, McKee MD, et al. A cell- autonomous requirement for neutral sphingomyelinase 2 in bone mineralization. Journal of Cell Biology 2011;194(2):277-89.
16. Duque G, Macoritto M, Dion N, Ste-Marie LG, Kremer R. 1, 25(OH)2D3 acts as a bone-forming agent in the hormone-independent senescence-accelerated mouse (SAM-P/6). American Journal of Physiology Endocrinology and Metabolism 2005;288(4):E723-30.
17. El Abdaimi K, Dion N, Papavasiliou V, Cardinal PE, Binderup L, Goltzman D, et al. The vitamin D analogue EB 1089 prevents skeletal metastasis and prolongs survival time in nude mice transplanted with human breast cancer cells. Cancer Research 2000;60(16):4412-8.
18. Recker RR, Kimmel DB, Parfitt AM, Davies KM, Keshawarz N, Hinders S. Static and tetracycline-based bone histomorphometric data from 34 normal postme- nopausal females. Journal of Bone and Mineral Research 1988;3(2):133-44.
19. Whyte MP, Wenkert D, Clements KL, McAlister WH, Mumm S. Bisphosphonate- induced osteopetrosis. New England Journal of Medicine 2003;349(5):457-63.
20. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. Journal of Clinical Endocrinology and Metabolism 2005;90(3):1294-301.
21. Seeman E, Delmas PD. Bone quality - the material and structural basis of bone strength and fragility. New England Journal of Medicine 2006;354(21): 2250-61.
22. Weinstein RS, Roberson PK, Manolagas SC. Giant osteoclast formation and long-term oral bisphosphonate therapy. New England Journal of Medicine 2009;360(1):53-62.
23. Cheung AM, Tile L, Cardew S, Pruthi S, Robbins J, Tomlinson G, et al. Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial. Lancet Oncology 2012;13(3):275-84.
24. Sornay-Rendu E, Boutroy S, Munoz F, Delmas PD. Alterations of cortical and trabecular architecture are associated with fractures in postmenopausal women, partially independent of decreased BMD measured by DXA: the OFELY study. Journal of Bone and Mineral Research 2007;22(3):425-33.
25. Stein EM, Liu XS, Nickolas TL, Cohen A, Thomas V, McMahon DJ, et al. Abnormal microarchitecture and reduced stiffness at the radius and tibia in postmenopausal women with fractures. Journal of Bone and Mineral Research 2010;25(12):2572-81.
26. Nishiyama KK, Macdonald HM, Moore SA, Fung T, Boyd SK, McKay HA. Cortical porosity is higher in boys compared with girls at the distal radius and distal tibia during pubertal growth: An HR-pQCT study. Journal of Bone and Mineral Research 2011:25.
27. Varga P, Pahr DH, Baumbach S, Zysset PK. HR-pQCT based FE analysis of the most distal radius section provides an improved prediction of Colles' fracture load in vitro. Bone 2010;47(5):982-8.
28. Van Poznak C. Managing bone mineral density with oral bisphosphonate therapy in women with breast cancer receiving adjuvant aromatase inhibition. Breast Cancer Research 2010;12(3):110.
29. Lester JE, Dodwell D, Purohit OP, Gutcher SA, Ellis SP, Thorpe R, et al. Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clinical Cancer Research 2008;14(19):6336-42.
30. Brufsky A, Bundred N, Coleman R, Lambert-Falls R, Mena R, Hadji P, et al. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor- associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist 2008;13(5):503-14.
31. Goss PE, Ingle JN, Ales-Martinez JE, Cheung AM, Chlebowski RT, Wactawski- Wende J, et al. Exemestane for breast-cancer prevention in postmenopausal women. New England Journal of Medicine 2011;364(25):2381-91.
32. Allen MR, Kubek DJ, Burr DB. Cancer treatment dosing regimens of zoledronic acid result in near-complete suppression of mandible intracortical bone remodeling in beagle dogs. Journal of Bone and Mineral Research 2010;25(1):98-105.
33. Allen MR, Burr DB. Bisphosphonate effects on bone turnover, microdamage, and mechanical properties: What we think we know and what we know that we do not know. Bone 2011;49(1):56-65.